Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells

Prostate

Volumn 73, Issue 10, 2013, Pages 1069-1081

  Wen, Juan ^a,b   Zhao, Yuan ^a,c   Li, Jinghe ^a   Weng, Chunyan ^a,b   Cai, Jingjing ^a,b   Yang, Kan ^b   Yuan, Hong ^b   Imperato Mcginley, Julianne ^a   Zhu, Yuan Shan ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

dihydrotestosterone; endothelial cells; estrogen; prostate cancer cells; VEGF

Indexed keywords

17ALPHA ESTRADIOL; ANDROSTANOLONE; CD31 ANTIGEN; ESTRADIOL; MESSENGER RNA; SEMAXANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ANDROGENS; ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL SIZE; DIHYDROTESTOSTERONE; ENDOTHELIAL CELLS; ESTRADIOL; ESTROGENS; HUMANS; INDOLES; MALE; MICE; PROSTATE; PROSTATIC NEOPLASMS; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84878467377     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22654     Document Type: Article

References (48)

1. van Moorselaar RJ, Voest EE,. Angiogenesis in prostate cancer: Its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol 2002; 197: 239-250.
2. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F, Keshet E,. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998; 95: 10820-10825.
3. Stewart RJ, Panigrahy D, Flynn E, Folkman J,. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001; 165: 688-693.
4. Joseph I, Nelson J, Denmeade S, Isaacs J,. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997; 3: 2507-2511.
5. Okihara K, Watanabe H, Kojima M,. Kinetic study of tumor blood flow in prostatic cancer using power Doppler imaging. Ultrasound Med Biol 1999; 25: 89-94.
6. Joseph IB, Isaacs JT,. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 1997; 57: 1054-1057.
7. Franck-Lissbrant I, Haggstrom S, Damber JE, Bergh A,. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139: 451-456.
8. Shabsigh A, Chang DT, Heitjan DF, Kiss A, Olsson CA, Puchner PJ, Buttyan R,. Rapid reduction in blood flow to the rat ventral prostate gland after castration: Preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998; 36: 201-206.
9. Shabisgh A, Tanji N, D'Agati V, Burchardt M, Rubin M, Goluboff ET, Heitjan D, Kiss A, Buttyan R,. Early effects of castration on the vascular system of the rat ventral prostate gland. Endocrinology 1999; 140: 1920-1926.
10. Zhu YS, Imperato-McGinley JL,. 5alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci 2009; 1155: 43-56.
11. Lissbrant IF, Lissbrant E, Damber JE, Bergh A,. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001; 35: 437-452.
12. Prins GS, Birch L, Greene GL,. Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 1991; 129: 3187-3199.
13. Gao J, Arnold JT, Isaacs JT,. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 2001; 61: 5038-5044.
14. Folkman J,. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
15. Papetti M, Herman IM,. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002; 282: C947-C970.
16. Schmid MC, Varner JA,. Myeloid cell trafficking and tumor angiogenesis. Cancer Lett 2007; 250: 1-8.
17. Karlou M, Tzelepi V, Efstathiou E,. Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol 2010; 7: 494-509.
18. Richard C, Kim G, Koikawa Y, Salm SN, Tsujimura A, Wilson EL, Moscatelli D,. Androgens modulate the balance between VEGF and angiopoietin expression in prostate epithelial and smooth muscle cells. Prostate 2002; 50: 83-91.
19. Ko YJ, Balk SP,. Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers. Curr Pharm Biotechnol 2004; 5: 459-470.
20. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'Amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C,. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002; 60: 1-6.
21. Knudsen KE, Scher HI,. Starving the addiction: New opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009; 15: 4792-4798.
22. Bush TL, Barrett-Connor E,. Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev 1985; 7: 89-104.
23. Oh WK,. The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 2002; 1: 81-89.
24. Qiao Y, Zhang ZK, Cai LQ, Tan C, Imperato-McGinley JL, Zhu YS,. 17alpha-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals. Prostate 2007; 67: 1719-1728.
25. Qiao Y, Wang L, Cai LQ, Tan C, Imperato-McGinley J, Zhu YS,. Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17alpha-estradiol in prostate cancer. J Urol 2011; 185: 305-314.
26. Zhu YS, Cai LQ, You X, Cordero JJ, Huang Y, Imperato-McGinley J,. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells. J Androl 2003; 24: 681-687.
27. Williams RL, Courtneidge SA, Wagner EF,. Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene. Cell 1988; 52: 121-131.
28. Crabtree MJ, Smith CL, Lam G, Goligorsky MS, Gross SS,. Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. Am J Physiol Heart Circ Physiol 2008; 294: H1530-H1540.
29. Cai J, Hong Y, Weng C, Tan C, Imperato-McGinley J, Zhu YS,. Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism. Am J Physiol Heart Circ Physiol 2011; 300: H1210-H1221.
30. Li Y, Cozzi PJ,. Angiogenesis as a strategic target for prostate cancer therapy. Med Res Rev 2010; 30: 23-66.
31. Niu YN, Xia SJ,. Stroma-epithelium crosstalk in prostate cancer. Asian J Androl 2009; 11: 28-35.
32. Zhu YS,. Molecular basis of steroid action in the prostate. Cellsci Rev 2005; 1: 27-55.
33. English HF, Drago JR, Santen RJ,. Cellular response to androgen depletion and repletion in the rat ventral prostate: Autoradiography and morphometric analysis. Prostate 1985; 7: 41-51.
34. Wang GM, Kovalenko B, Huang Y, Moscatelli D,. Vascular endothelial growth factor and angiopoietin are required for prostate regeneration. Prostate 2007; 67: 485-499.
35. Zhu YS, Cai LQ, Huang Y, Fish J, Wang L, Zhang ZK, Imperato-McGinley JL,. Receptor isoform and ligand-specific modulation of dihydrotestosterone-induced prostate specific antigen gene expression and prostate tumor cell growth by estrogens. J Androl 2005; 26: 500-508; 509-510.
36. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O,. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 1998; 95: 15677-15682.
37. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M, Gustafsson JA,. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 2001; 98: 6330-6335.
38. Ling S, Komesaroff P, Sudhir K,. Cellular mechanisms underlying the cardiovascular actions of oestrogens. Clin Sci (Lond) 2006; 111: 107-118.
39. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, Kleinman HK, Schnaper HW,. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 1995; 91: 755-763.
40. Kawagoe J, Ohmichi M, Tsutsumi S, Ohta T, Takahashi K, Kurachi H,. Mechanism of the divergent effects of estrogen on the cell proliferation of human umbilical endothelial versus aortic smooth muscle cells. Endocrinology 2007; 148: 6092-6099.
41. Zaitseva M, Yue DS, Katzenellenbogen JA, Rogers PA, Gargett CE,. Estrogen receptor-alpha agonists promote angiogenesis in human myometrial microvascular endothelial cells. J Soc Gynecol Investig 2004; 11: 529-535.
42. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J,. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
43. Aragon-Ching JB, Dahut WL,. VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol 2009; 2: 161-168.
44. Gale NW, Thurston G, Davis S, Wiegand SJ, Holash J, Rudge JS, Yancopoulos GD,. Complementary and coordinated roles of the VEGFs and angiopoietins during normal and pathologic vascular formation. Cold Spring Harb Symp Quant Biol 2002; 67: 267-273.
45. Eriksson U, Alitalo K,. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol 1999; 237: 41-57.
46. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F,. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189.
47. Wang GM, Kovalenko B, Wilson EL, Moscatelli D,. Vascular density is highest in the proximal region of the mouse prostate. Prostate 2007; 67: 968-975.
48. Lissbrant IF, Hammarsten P, Lissbrant E, Ferrara N, Rudolfsson SH, Bergh A,. Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice. Prostate 2004; 58: 57-65.